Compugen Ltd. (USA) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CGEN Nasdaq 8731 http://cgen.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Compugen Ltd. (USA)

12 Best One Dollar Stocks to Buy According To Hedge Funds - Jan 27th, 2023 2:32 pm
Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview - Jan 23rd, 2023 12:00 pm
Why Shares of Compugen Rose on Thursday - Dec 29th, 2022 9:53 pm
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer - Dec 6th, 2022 12:00 pm
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients - Dec 1st, 2022 12:00 pm
Why Shares of Compugen Rose 16.5% on Wednesday - Nov 30th, 2022 9:49 pm
Compugen to Participate in the JMP Securities Hematology and Oncology Summit - Nov 29th, 2022 12:00 pm
Why Shares of Compugen Jumped 17.86% on Thursday - Nov 17th, 2022 9:51 pm
Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecific - Nov 16th, 2022 12:00 pm
Why Compugen Stock Crumbled Today - Nov 14th, 2022 11:52 pm
Compugen Reports Third Quarter 2022 Results - Nov 14th, 2022 12:00 pm
Compugen to Participate in the Stifel Healthcare Conference - Nov 8th, 2022 12:00 pm
Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients - Nov 7th, 2022 1:00 pm
Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients - Nov 7th, 2022 1:00 pm
Compugen Announces Receipt of Nasdaq Delisting Notice - Nov 2nd, 2022 11:00 am
Why Shares of Compugen Jumped 9.27% on Tuesday - Nov 1st, 2022 8:41 pm
Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022 - Oct 31st, 2022 11:00 am
Compugen to Present New Clinical Data at ESMO-IO - Oct 26th, 2022 11:00 am
Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022 - Oct 6th, 2022 11:00 am
Compugen Letter to Shareholders - Sep 22nd, 2022 11:00 am